MedTrace Logo

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV

NCT06724640 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2025-10-29

No results posted yet for this study

Summary

The purpose of this study is to investigate safety, pharmacokinetics and tolerability following single ascending dose (SAD) and multiple ascending doses (MAD) of VH4011499 administered subcutaneously (SC) and intramuscularly (IM) in participants without HIV.

Conditions

  • HIV Infections

Interventions

DRUG

VH4011499 low dose Injection

VH4011499 low dose Injection will be administered subcutaneously and/or intramuscularly.

DRUG

VH4011499 high dose Injection

VH4011499 high dose Injection will be administered subcutaneously and/or intramuscularly.

DRUG

Placebo

Placebo Injection will be administered either subcutaneously or intramuscularly.

Sponsors & Collaborators

  • ViiV Healthcare

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-16
Primary Completion
2028-08-16
Completion
2028-08-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06724640 on ClinicalTrials.gov